北陆药业: 募集资金使用管理办法

Core Points - The document outlines the management and usage of raised funds by Beijing Beilu Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations [2][3][4] - The company is required to ensure that the use of raised funds aligns with the commitments made in the prospectus and cannot change the intended use without shareholder approval [3][4][6] - The document specifies the establishment of special accounts for raised funds, which must be managed separately from other funds [4][5][6] Fund Management - The company must conduct verification of raised funds by a qualified accounting firm and disclose the status of these funds in annual reports [4][6][7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank where the funds are stored [6][7][8] - The company is required to ensure that raised funds are used for main business activities and cannot be used for high-risk investments or financial investments [9][10][11] Fund Usage - The company must follow the investment plan as stated in the issuance application and disclose any significant deviations from the plan [9][10][11] - Any changes in the use of raised funds must be approved by the board of directors and independent directors, and disclosed to shareholders [12][13][14] - The company must report on the progress of investment projects every six months and provide a special report on the use of raised funds [18][19][20] Fund Supervision - The internal audit department must check the status of raised funds at least quarterly and report findings to the board [36][37] - Independent directors can hire accounting firms to verify the use of raised funds if discrepancies are found [20][21] - Any violations in the use of raised funds that result in losses to the company will hold responsible personnel accountable [21][22]